REFERENCES
1. Arora S, Scott AM, Janes PW. ADAM proteases in cancer: biological roles, therapeutic challenges, and emerging opportunities. Cancers. 2025;17:1703.
2. Chou CW, Huang YK, Kuo TT, Liu JP, Sher YP. An overview of ADAM9: structure, activation, and regulation in human diseases. Int J Mol Sci. 2020;21:7790.
3. Parry DA, Toomes C, Bida L, et al. Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice. Am J Hum Genet. 2009;84:683-91.
4. Liu JP, Shen KY, Cheng WC, et al. ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression. Am J Cancer Res. 2024;14:1850-65.
5. Slapak EJ, El Mandili M, Brink MST, Kros A, Bijlsma MF, Spek CA. Preclinical assessment of ADAM9-responsive mesoporous silica nanoparticles for the treatment of pancreatic cancer. Int J Mol Sci. 2023;24.
6. Huang YK, Cheng WC, Kuo TT, et al. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. Nat Cancer. 2024;5:400-19.
7. Le TT, Hsieh CL, Lin IH, et al. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer. Am J Cancer Res. 2022;12:176-97.
8. Wu S, Cheng L, Luo T, Makeudom A, Wang L, Krisanaprakornkit S. Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) in relation to poor prognosis of patients with oral squamous cell carcinoma. Discov Oncol. 2024;15:582.
9. Ao T, Mochizuki S, Kajiwara Y, et al. Cancer-associated fibroblasts at the unfavorable desmoplastic stroma promote colorectal cancer aggressiveness: potential role of ADAM9. Int J Cancer. 2022;150:1706-21.
10. Romanowicz A, Lukaszewicz-Zajac M, Mroczko B. Exploring potential biomarkers in oesophageal cancer: a comprehensive analysis. Int J Mol Sci. 2024;25:4253.
11. Micocci KC, Moritz MN, Lino RL, et al. ADAM9 silencing inhibits breast tumor cells transmigration through blood and lymphatic endothelial cells. Biochimie. 2016;128-129:174-82.
12. Zhang XY, Zhao CY, Dong JM, et al. ADAM9 mediates Cisplatin resistance in gastric cancer cells through DNA damage response pathway. Med Oncol. 2025;42:122.
13. Jotatsu Y, Sung SY, Wu MH, et al. An antibody of the secreted isoform of disintegrin and metalloprotease 9 (sADAM9) inhibits epithelial-mesenchymal transition and migration of prostate cancer cell lines. Int J Mol Sci. 2024;25:6646.
14. Ding YF, Ho KH, Lee WJ, et al. Cyclic increase in the histamine receptor H1-ADAM9-Snail/Slug axis as a potential therapeutic target for EMT-mediated progression of oral squamous cell carcinoma. Cell Death Dis. 2025;16:191.
15. Banerjee S, Padhye S, Azmi A, et al. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 2010;62:938-46.
16. Ahmad A, Mishra RK, Vyawahare A, et al. Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: chemistry and biological effects. Saudi Pharm J. 2019;27:1113-26.
17. Wei C, Zou H, Xiao T, et al. TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway. J Cell Mol Med. 2021;25:10101-10.
18. Mollica V, Rizzo A, Massari F. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncol. 2020;16:2029-33.
19. Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.
20. Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.
21. Liao C, Wang X. TCGAplot: an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data. BMC Bioinformatics. 2023;24:483.
22. Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18-27.
23. Zhang L, Wei C, Li D, et al. COVID-19 receptor and malignant cancers: association of CTSL expression with susceptibility to SARS-CoV-2. Int J Biol Sci. 2022;18:2362-71.
24. Jiang L, Huang W, Cao M, et al. Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches. Sci Rep. 2024;14:26432.
25. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605-12.
26. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: an open chemical toolbox. J Cheminform. 2011;3:33.
27. Zheng R, Wan C, Mei S, et al. Cistrome data browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47:D729-35.
28. Lin CY, Chen HJ, Huang CC, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74:5229-43.
29. Lin CY, Cho CF, Bai ST, et al. ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT. Sci Rep. 2017;7:15108.
30. Sher YP, Wang LJ, Chuang LL, et al. ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells. PLoS ONE. 2014;9:e94065.
31. Lin YW, Wen YC, Lin CY, et al. Genetic variants of ADAM9 as potential predictors for biochemical recurrence in prostate cancer patients after receiving a radical prostatectomy. Int J Med Sci. 2024;21:2934-42.
32. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
33. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-4.
34. Pan C, Chen H, Yang B. Licochalcone a inhibits proliferation and metastasis of colon cancer by regulating miR-1270/ADAM9/Akt/NF-κB axis. Iran J Public Health. 2023;52:1962-72.
35. AmeliMojarad M, AmeliMojarad M, Wang J, Tavakolpour V, Shariati P. A pan-cancer study of ADAM9’s immunological function and prognostic value particularly in liver cancer. Sci Rep. 2024;14:26862.
36. Li J, Ji Z, Qiao C, Qi Y, Shi W. Overexpression of ADAM9 promotes colon cancer cells invasion. J Invest Surg. 2013;26:127-33.
37. Forbes SA, Beare D, Boutselakis H, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777-83.
38. Drobiova H, Al-Mulla F, Al-Temaimi R. ADAM9 genetic variants and their role in modulating enzyme activity in diabetes and metabolic traits. J Diabetes Res. 2025;2025:5519447.
39. Ilieva M, Tschaikowski M, Vandin A, Uchida S. The current status of gene expression profilings in COVID-19 patients. Clin Transl Discov. 2022;2:e104.
40. Ibor OY, Ekpenyong B, Charles M. A, Kenneth E. M. Review on gene and cell therapies in prostate cancer treatment: prospects and challenges. J Transl Genet Genom. 2025;9:62-75.
41. Chen CM, Hsieh YH, Hwang JM, et al. Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2. Tumour Biol. 2015;36:3407-15.
42. Wang JJ, Zou JX, Wang H, et al. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling. Acta Pharmacol Sin. 2019;40:1067-75.
43. Liu R, Gu J, Jiang P, et al. DNMT1-microRNA126 epigenetic circuit contributes to esophageal squamous cell carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res. 2015;21:854-63.
44. Liu CM, Hsieh CL, He YC, et al. In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression. PLoS ONE. 2013;8:e53795.
45. Giebeler N, Schönefuß A, Landsberg J, Tüting T, Mauch C, Zigrino P. Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis. Oncogene. 2017;36:5058-67.
